Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Tumor-infiltrating lymphocytes in breast cancer: ready for prime time?

Ocaña A, Diez-Gónzález L, Adrover E, Fernández-Aramburo A, Pandiella A, Amir E.

J Clin Oncol. 2015 Apr 10;33(11):1298-9. doi: 10.1200/JCO.2014.59.7286. Epub 2015 Mar 9. No abstract available.

PMID:
25753437
2.

Tumor-infiltrating lymphocytes in triple-negative breast cancer: a biomarker for use beyond prognosis?

Tsoutsou PG, Bourhis J, Coukos G.

J Clin Oncol. 2015 Apr 10;33(11):1297-8. doi: 10.1200/JCO.2014.59.2808. Epub 2015 Mar 9. No abstract available.

PMID:
25753438
3.
4.

Reply to A. Ocaña et al and P.G. Tsoutsou et al.

Loi S.

J Clin Oncol. 2015 Apr 10;33(11):1299-300. doi: 10.1200/JCO.2014.59.9423. Epub 2015 Mar 9. No abstract available.

PMID:
25753442
5.

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

Tung NM, Winer EP.

J Clin Oncol. 2015 Mar 20;33(9):969-71. doi: 10.1200/JCO.2014.59.6031. Epub 2015 Jan 5. No abstract available.

PMID:
25559817
6.

Are mammaglobin and GCDFP-15 sensitive markers for diagnosis of metastatic basal-like triple negative breast carcinomas?

Rakhshanı N, Daryakar A.

Turk Patoloji Derg. 2014;30(1):18-22. doi: 10.5146/tjpath.2013.01202. Epub 2013 Nov 7.

7.

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE.

Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8.

8.

Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?

Chiorean R, Braicu C, Berindan-Neagoe I.

Breast. 2013 Dec;22(6):1026-33. doi: 10.1016/j.breast.2013.08.007. Epub 2013 Sep 21. Review.

PMID:
24063766
9.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S.

J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.

PMID:
25534375
10.

Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.

Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J, Tan PH.

Mod Pathol. 2014 Mar;27(3):352-60. doi: 10.1038/modpathol.2013.145. Epub 2013 Aug 9.

11.

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.

Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ.

BMC Cancer. 2014 Jan 31;14:51. doi: 10.1186/1471-2407-14-51.

12.

Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.

Uchôa Dde M, Graudenz MS, Callegari-Jacques SM, Hartmann CR, Ferreira BP, Fitarelli-Kiehl M, Edelweiss MI.

Pathol Res Pract. 2014 Jul;210(7):432-9. doi: 10.1016/j.prp.2014.03.005. Epub 2014 Mar 27.

PMID:
24726267
13.

Clinicopathologic features of triple negative breast cancers: an experience from Pakistan.

Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, Khan M.

Diagn Pathol. 2014 Feb 28;9:43. doi: 10.1186/1746-1596-9-43.

14.

Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour.

Elsawaf Z, Sinn HP, Rom J, Bermejo JL, Schneeweiss A, Aulmann S.

Breast. 2013 Oct;22(5):986-92. doi: 10.1016/j.breast.2013.05.012. Epub 2013 Jun 24.

PMID:
23806603
15.

Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.

Gorshein E, Klein P, Boolbol SK, Shao T.

Clin Breast Cancer. 2014 Oct;14(5):309-14. doi: 10.1016/j.clbc.2014.02.007. Epub 2014 Mar 3.

PMID:
24703318
16.

Lymphocytes prognostic in breast cancer.

Sklan A.

Lancet Oncol. 2014 Sep;15(10):e422. No abstract available.

PMID:
25328947
17.

Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.

Droeser R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, Oertli D, Tapia C.

BMC Cancer. 2012 Apr 3;12:134. doi: 10.1186/1471-2407-12-134.

18.

Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.

Tamiolakis D, Simopoulos C, Cheva A, Lambropoulou M, Kotini A, Jivannakis T, Papadopoulos N.

Eur J Gynaecol Oncol. 2002;23(5):433-6.

PMID:
12440819
19.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
20.

Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.

Kuba S, Ishida M, Nakamura Y, Yamanouchi K, Minami S, Taguchi K, Eguchi S, Ohno S.

Jpn J Clin Oncol. 2014 Nov;44(11):1025-31. doi: 10.1093/jjco/hyu126. Epub 2014 Aug 25.

PMID:
25156682

Supplemental Content

Support Center